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Abstract
Background: Runt-related transcription factor 3 (RUNX3) is a tumor suppressor of cancer and appears to be an important
component of the transforming growth factor-beta (TGF-ß)-induced tumor suppression pathway. Surprisingly, we found
that RUNX3 expression level in head and neck squamous cell carcinoma (HNSCC) tissues, which is one of the most common
types of human cancer, was higher than that in normal tissues by a previously published microarray dataset in our
preliminary study. Therefore, here we examined the oncogenic role of RUNX3 in HNSCC.
Principal Findings: Frequent RUNX3 expression and its correlation with malignant behavior were observed in HNSCC.
Ectopic RUNX3 overexpression promoted cell growth and inhibited serum starvation-induced apoptosis and
chemotherapeutic drug induced apoptosis in HNSCC cells. These findings were confirmed by RUNX3 knockdown.
Moreover, RUNX3 overexpression enhanced tumorsphere formation. RUNX3 expression level was well correlated with the
methylation status in HNSCC cells. Moreover, RUNX3 expression was low due to the methylation of its promoter in normal
oral epithelial cells.
Conclusions/Significance: Our findings suggest that i) RUNX3 has an oncogenic role in HNSCC, ii) RUNX3 expression
observed in HNSCC may be caused in part by demethylation during cancer development, and iii) RUNX3 expression can be
a useful marker for predicting malignant behavior and the effect of chemotherapeutic drugs in HNSCC.
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Introduction
RUNX3/AML2/PEBP2C/CBFA3 is a transcription factor and
one of the Runt-related (RUNX) family. Three members of the
Runx family genes, RUNX1, RUNX2 and RUNX3, and related
gene, CBFB/Pebpb2, are all known as the developmental regulators
and have been shown to be important in human cancers [1].
RUNX3 was originally cloned as AML2 and is localized on
chromosome 1p36.1 [2]. RUNX3 has multiple functions and was
at first reported to correlate with the genesis and progression of
human gastric cancer as a tumor suppressor [2]. Runx3-null mice
exhibit hyperplasia of gastric mucosa as a result of stimulated
proliferation and suppressed apoptosis of epithelial cells [3]. In
fact, RUNX3 is inactivated in more than 80% of human gastric
cancer by gene silencing and protein mislocalization [4]. Besides
gastric cancer, it has been reported that reduced expression of
RUNX3 was observed in various cancers including bladder, liver,
colorectal and lung cancers [5–8]. In these tumors, reduced
expression of RUNX3 was frequently caused by CpG island
hypermethylation [9]. Moreover, point mutations of RUNX3 were
observed in certain type of human cancers including gastric and
bladder cancers [3,5]. Taken together, RUNX3 acts as a tumor
suppressor in various cancers.
Head and neck squamous cell carcinoma (HNSCC) is one of the
most common types of human cancer, with an annual incidence of
more than 500,000 cases worldwide [10]. Like most epithelial
cancers, HNSCC develops through the accumulation of multiple
genetic and epigenetic alterations in a multi-step process [11].
Surprisingly, we found that RUNX3 expression level in HNSCC
tissues was higher than that in normal tissues by a previously
published microarray dataset of 41 HNSCC patients and 13 normal
controls in our preliminary study [12] (Figure 1A). Interestingly, it
recently has been reported that RUNX3 overexpression was
observed in basal cell carcinoma of skin [13]. Therefore, we thought
that RUNX3 might have an oncogenic role in HNSCC as well as in
basal cell carcinoma of skin. In the present study, we examined the
expression and roles of RUNX3 for HNSCC development.
Materials and Methods
Reagents
Transforming growth factor ß1 (TGF-ß), basic fibroblast growth
factor (bFGF) and Platelet-derived growth factor-AA (PDGF-AA)
were obtained from R&D systems (Minneapolis, MN). Insulin
growth factor (IGF) was obtained from Sigma (Saint Louis, MO).
Epidermal growth factor (EGF) was obtained from Pepro Tech
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EC (London, UK). Adriamycin (Doxorubicin hydrochloride) was
obtained from Sigma.
Cell lines and tissue samples
HNSCC cell lines (HSC2, HSC3, HSC4, Ca9-22, Ho-1-U-1
and Ho-1-N-1) were provided by Japanese Collection of Research
Bioresources Cell Bank. HNSCC cell lines (ZA, HOC719-PE,
HOC-719-NE, HOC621, HOC119, HOC313, TSU and OMI)
were kindly provided by Dr. Kamata (Hiroshima University).
Gastric cancer cell lines (MKN-1 and MKN-45), colon cancer cell
lines (RKO and HCT116), breast cancer cell lines (MCF7 and
SK-BR3), lymphoma cell line (U937) and leukemia cell line (HL-
Figure 1. Expression of RUNX3 mRNA and protein in HNSCC. A: Total RNA from 41 primary HNSCC and 13 normal tissues was labeled and
hybridized to Affymetrix U133A Gene Chips as previously reported. Graph shows the average of signal intensity of RUNX3 in 41 HNSCC and 13 normal
tissues in microarray analysis. RUNX3 expression level in HNSCC is higher than that of normal tissues. B: Expression of RUNX3 mRNA in 14 HNSCC cell
lines (HSC2, HSC3, HSC4, Ca9-22, Ho-1-N-1, Ho-1-U-1, ZA, HOC719-PE, HOC719-NE, HOC621, HOC119, HOC313, TSU and OMI) by RT-PCR. GAPDH was
used as a control. C: Expression of RUNX3 mRNA in various cancer cell lines including colon cancer (RKO and HCT116), gastric cancer (MKN-1 and
MKN-45), leukemia (HL60), lymphoma (U937) and breast cancer (MCF7 and SK-BR3). GAPDH was used as a control. D: Expression of RUNX3 mRNA in
18 HNSCC cases by RT-PCR. GAPDH was used as a control. E: Expression of RUNX3 protein in 6 HNSCC cell lines (HSC2, HSC3, HSC4, Ca9-22, Ho-1-N-1
and Ho-1-U-1) was examined by Western blot analysis. Cul1 expression was used as a loading control.
doi:10.1371/journal.pone.0005892.g001
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60) were provided by Japanese Collection of Research Bior-
esources Cell Bank. They were maintained in RPMI-1640 or
Dulbecco’s Modified Eagle Medium (Nissui Pharmaceutical Co.,
Tokyo, Japan) supplemented with 10% heat-inactivated FBS
(Invitrogen) and 100 U/ml penicillin-streptomycin (Gibco) under
conditions of 5% CO2 in air at 37uC. For growth assay, 5000 cells
were plated onto 24 well plates (Falcon), and trypsinized cells
counted at 0, 2, 4, 6 day by Cell Counter (Coulter Z1). Tongue
tissues of mouse embryos at embryonic day 15.5 and 10 weeks old
BALB/c mice were used for histology and immunohistochemistry.
The experimental protocols were approved by the Animal Care
and Use Committee of Hiroshima University.
Tissue samples of HNSCC were retrieved from the Surgical
Pathology Registry of Hiroshima University Hospital, after
approval by the Ethical Committee of Hiroshima University
Hospital. Each patient gave written informed consent. Fifty-two
cases of HNSCC and 9 normal oral mucosal tissues were used in
this study. Five colon cancer tissues were also used for
immunohistochemistry analysis (kindly provided by Dr. Shima-
moto, Prefectural University of Hiroshima).
10% buffered-formalin fixed and paraffin embedded tissues
were used for immunohistochemical examination. The histological
grade and stage of tumor were classified according to the criteria
of the Japan Society for Head and Neck Cancer. Fresh samples
were taken from the HNSCC tissues for RT-PCR analysis.
RT-PCR
Total RNA was isolated from cultures of confluent cells using
the RNeasy Mini Kit (Qiagen). Preparations were quantified and
their purity was determined by standard spectrophometric
methods. cDNA was synthesized from 1 mg total RNA according
to the ReverTra Dash (Toyobo Biochemicals, Tokyo, Japan). PCR
amplification of RUNX3 was done using forward primer; 59-
CAGAAGCTGGAGGACCAGAC-39 and reverse primer; 59-
TCGGAGAATGGGTTCAGTTC-39. GAPDH was used as a
control. Aliquots of total cDNA were amplified with Go TaqH
Green Master Mix (Promega), and amplifications were performed
in a PC701 thermal cycler (Astec, Fukuoka, Japan) for 30 cycles
after an initial 30 sec denaturation at 94uC, annealed for 30 sec at
60uC, and extended for 1 min at 72uC in all primers. The
amplification reaction products were resolved on 1.5% agarose/
TAE gels (Nacalai tesque, Inc., Kyoto, Japan), electrophoresed at
100 mV, and visualized by ethidium-bromide staining.
Western blot analysis
Western blotting was carried out as we described previously
[14]. An anti-RUNX3 monoclonal antibody (R3-5G4, kindly
provided by Dr. Ito, Institute of Molecular and Cell Biology,
Singapore), anti-FLAG monoclonal antibody (M2, Sigma) and
anti-Cul1 polyclonal antibody (Zymed) were used. Thirty mg of
protein was subjected to 10% polyacrylamide gel electrophoresis
followed by electroblotting onto a nitrocellulose filter. For
detection of the immuno-complex, the ECL western blotting
detection system (Amersham) was used.
Immunohistochemical staining
Immunohistochemical detection of RUNX3 in HNSCC cases
was performed on 4.5 mm sections mounted on silicon-coated glass
slides, using a streptavidin-biotin peroxidase technique as
described previously [14]. Immunohistochemical detection of
Runx3 in human various cancer cases including 3 esophagus
cancers, 3 gastric cancers, 3 colon cancers, 3 rectum cancers, 3
pancreas cancers, 3 liver cancers, 3 lung cancers, 3 kidney cancers,
3 bladder cancers, and 4 uterus cancers was performed using tissue
microarray (MBL Co. Ltd., Nagoya, Japan). For immunohisto-
chemical study, an anti-RUNX3 monoclonal antibody (R3-6E9,
kindly provided by Dr. Ito, Institute of Molecular and Cell
Biology, Singapore) was used. For immunohistochemical study of
mouse tissues, an anti-Runx3 monoclonal antibody (R3-1E10,
MBL Co. Ltd.) was used. The expression of RUNX3 was graded
as positive (over 5% of tumor or epithelial cells showed
immunopositivity) and negative (less than 5% of tumor or
epithelial cells showed weak or focal immunopositivity or no
staining). Three pathologists (Y.K., I.O., and T.T.) made all the
assessments. Possible correlation between variables of the analyzed
tumor samples was tested for association by the Fisher’s exact test.
A P value,0.05 was required for significance.
5-aza-29-deoxycytidine treatment
HSC4 cells and normal epithelial cells were treated with
medium containing 300 nM 5-aza-29-deoxycytidine (5-aza-dC,
Sigma) for 72 h. After treatment, cells were collected and
examined the expression of RUNX3 mRNA by RT-PCR.
Bisulfite modification and methylation-specific
polymerase chain reaction (PCR)
Genomic DNA from cells or tissues was extracted using the
DNeasy Kit (Qiagen, Hilden, Germany). Fifty micro liters of the
supernatant were used directly as a source of DNA for sodium
bisulfite treatment. DNA samples were treated with bisulfite to
convert all unmethylated cytosines to uracils whilst leaving
methylated cytosines unaffected. DNA was denatured by NaOH
(final concentration, 0.2 M) for 10 min at 37uC. Thirty ml of 10 mM
hydroquinone (Sigma) and 520 ml of 3 M sodium bisulfite (Sigma) at
pH 5.0 both freshly prepared, were added and mixed, and samples
were incubated at 50uC for 16 h. Modified DNA was purified using
Wizard DNA purification resin (Promega) and eluted into 50 ml of
water. Modification was completed by NaOH (final concentration,
0.3 M) treatment for 5 min at room temperature, followed by
ethanol precipitation. Modified DNAs were amplified in a 20 mL
reaction volume containing 2 mL 106PCR buffer with 15 mM
MgCl2, 4 mL 5xQ-Solution, 10 pM of each primer, 0.2 mM dNTPs
and 0.75 U Taq polymerase (HotStar Taq DNA polymerase;
Qiagen, Hilden, Germany). After the mixture was heated at 95uC
for 15 min, PCRwas performed in a thermal cycler (GeneAmp 2400;
PE Applied Biosystems, Foster City, CA, USA) for 35 cycles of
denaturation at 94uC for 30 sec, annealing at 58uC for 60 sec, and
extension at 72uC for 60 sec, followed by a final 10 min extension at
72uC. The PCR products were separated on a 8% non-denaturing
polyacrylamide gel. RUNX3 CpG island and analyzed regions
(No. 1–10) are shown in Figure 2B. The primer sets used in this study
were listed in Table S1 (GenBank accession number AL023096) [15].
Generation of RUNX3-overexpressing HNSCC cells
A RUNX3 expression plasmid, pcDNA3 encoding FLAG
tagged RUNX3 cDNA, was kindly provided by Dr. Ito (Institute
of Molecular and Cell Biology, Singapore). The RUNX3/
pcDNA3 plasmid or the vector alone was introduced into HSC3
cells, and then G418 (500 mg/ml, Gibco) was added to the culture
medium after 48 h of transfection. After 2 weeks of G418
selection, we obtained the stable pool clones. Cell transfections
were performed using FuGENE 6 (Roche) according to the
manufacture’s instruction.
Silencing by Small Interfering RNA
Logarithmically growing Ca9-22 cells were seeded at a density
of 105cells/6 cm dish and transfected with oligos twice (at 24 and
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48 h after replating) using Oligofectamine (Invitrogen) as de-
scribed [16]. Forty-eight hours after the last transfection, lysates
were prepared and analyzed by SDS-PAGE and immunoblotting.
The siRNA is a 19-bp duplex oligoribonucleotide with a sense
strand corresponding to nucleotides 275–293 of human RUNX3
mRNA sequence; 59-ccuucaaggugguggcauu-39. A scrambled
sequence that does not show significant homology to rat, mouse
or human gene sequences was used as a control.
Flow cytometric analysis
Cell cycle distribution was determined by DNA content analysis
after propidium iodide staining. Cells were cultured as described
above, and fixed in 70% ethanol and stored at 4uC before analysis.
Flow cytometric determination of DNA content was analyzed by a
FACS calibur (Becton-Dickinson, San Jose, CA) flow cytometer.
For each sample, 20,000 events were stored.
Annexin V and Propidium Iodide Dual-Staining Assay
After serum starvation or Dox treatment, the cells were then
stained with fluorescein isothiocyanate (FITC)-conjugated An-
nexin V and propidium iodide (PI), using the Annexin V-FITC
Apoptosis Detection kit (Becton-Dickinson) according to the
manufacturer’s instructions. Apoptotic cells were identified by
dual-staining with recombinant FITC-conjugated with Annexin V
and propidium iodide (PI). Data acquisition and analysis were
done in a FACSCalibur (Becton-Dickinson) flow cytometer using
CellQuest software.
Results
Highly expression of RUNX3 in HNSCC
First, we examined the expression of RUNX3 in 14 HNSCC
cell lines (HSC2, HSC3, HSC4, Ca9-22, Ho-1-U-1, Ho-1-N-1,
ZA, HOC719-PE, HOC719-NE, HOC621, HOC119, HOC313,
TSU, and OMI). RUNX3 mRNA was observed in 9 of 14
HNSCC cell lines (Figure 1B). In certain type of human cancers
including gastric and bladder, it has been reported that point
mutations of RUNX3 were observed [3,5]. However, no
mutations were found in HNSCC cell lines with RUNX3 mRNA
expression (Ca9-22, Ho-1-U-1 and Ho-1-N-1) (data not shown).
RUNX3 mRNA expression was also examined in various cancer
cell lines including colon cancer (RKO and HCT116), gastric
cancer (MKN-1 and MKN-45), leukemia (HL60), lymphoma
(U937) and breast cancer (MCF7 and SK-BR3) (Figure 1C).
RKO, MCF7 and SK-BR3 cells did not express RUNX3 mRNA.
As previously reported, RUNX3 expression was well correlated
with methylation status, except for SK-BR3 cells [17–20]. In SK-
BR3 cells, down-regulation of RUNX3 is thought to be caused by
unknown mechanism [20]. We also examined the expression of
RUNX3 mRNA in 18 HNSCC tissues. In 13 of 18 (72.2%)
Figure 2. Immuno-expression of RUNX3 in HNSCC. A: Expression of RUNX3 was examined in skin epithelium (6100 and6250, upper panel),
normal oral mucosae (6100 and6250, middle panel) and normal oral mucosae with infiltration of chronic inflammatory cells (6100 and6250, lower
panel). In skin epithelium, some of epidermal cells showed RUNX3 expression in its nuclei. In normal oral mucosal tissues, only a few epithelial cells in
basal layer expressed RUNX3 in their nuclei, and most epithelial cells did not express RUNX3. In normal oral mucosae with infiltration of chronic
inflammatory cells, lymphocytes infiltrating into oral mucosa showed RUNX3 expression. B: Expression of RUNX3 was examined in HNSCC cases
(6100). Most cancer cells expressed RUNX3 in their nuclei.
doi:10.1371/journal.pone.0005892.g002
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HNSCC tissues, RUNX3 mRNA expression was observed
(Figure 1D). Next, RUNX3 protein expression was examined by
Western blot analysis in 6 HNSCC cells (HSC2, HSC3, HSC4,
Ca9-22, Ho-1-U-1 and Ho-1-N-1) (Figure 1E). Among them, Ca9-
22, Ho-1-U-1 and Ho-1-N-1 cells expressed RUNX3 protein,
corresponding to mRNA expression. Then, we examined RUNX3
expression in 9 normal oral mucosal tissues and 52 HNSCC cases
by immunohistochemistry. First, we used skin epithelium and
colon mucosa for reactivity of RUNX3 expression. As shown in
recent report [13], epidermal cells also showed RUNX3
expression in its nuclei (Figure 2A, upper panel). We also
examined the RUNX3 expression in colon cancer. In colon
cancer, RUNX3 is thought to be a tumor suppressor gene [18]. As
previously reported [18], RUNX3 expression was observed in its
nuclei of normal mucosa, while colon cancer cells did not express
RUNX3 (Figure S1). In normal oral mucosal tissues, only a few
epithelial cells in basal layer slightly expressed RUNX3 in their
nuclei, and most epithelial cells did not express (Figure 2A, middle
panel). Lymphocytes infiltrating into normal oral mucosa showed
RUNX3 expression (Figure 2A, lower panel). Immunopositivity of
RUNX3 in lymphocytes was used as a positive control of staining.
On the other hand, most cancer cells expressed RUNX3 in their
nuclei (Figure 2B). We also confirmed that nuclear expression of
RUNX3 by using nuclear and cytoplasmic fraction of HNSCC
cell lines, indicating no protein mislocalization (data not shown).
RUNX3 expression was frequently observed in 50% (26 of 52) of
HNSCC cases (Table 1). Moreover, we compared RUNX3
expression with clinico-pathological findings including differenti-
ation, invasiveness and metastasis. Interestingly, RUNX3 expres-
sion was well correlated with malignant behaviors including poorly
differentiation, invasiveness and metastasis (Table 1).
Methylation status of RUNX3 was well correlated with its
mRNA expression in HNSCC
We asked how RUNX3 expression was caused by in HNSCC.
Reduced expression of RUNX3 was frequently caused by CpG
island hypermethylation in various types of cancer [9]. In fact,
RUNX3 expression was observed in HSC4 cells without RUNX3
expression after 5-aza-29-deoxycytidine treatment (Figure 3A).
Homma et al. examined the methylation status of multiple regions
of RUNX3 promoter CpG island (3478 bp) within the proximal
promoter (No. 1–10) in gastric cancers and found that methylation
at the region spanning the transcription start site (No. 5–8) is
critical for loss of the RUNX3 expression (Figure 3B) [15]. To
examine the RUNX3 methylation status in HNSCC, we analyzed
the methylation of RUNX3 at all promoter regions (No. 1–10) by
methylation-specific PCR on the panel of HNSCC cell lines
(Figure 3C and 3D). HNSCC cells with RUNX3 expression
showed unmethylation or partially methylation at No. 5–8 region
(Figure 3D). HNSCC cells without RUNX3 expression showed
fully methylation at No. 5 and No. 6 region. Thus, methylation
status of the RUNX3 promoter region was well correlated with
RUNX3 mRNA expression in HNSCC cell lines.
Recent report shows that Runx3 is expressed in the tongue and
palate epithelium of mouse embryos from embryonic day 12.5 to
16.5, and that Runx3 expression decreases after embryonic day 16.5
and disappears in newborn mice [21]. Here we also confirmed that
Runx3 expression was observed in tongue epithelium of mouse
embryos (E15.5), but not in adult mouse tongue epithelium (10
weeks old) (Figure 3E). These findings made us hypothesize that
RUNX3 might be silenced by methylation in adult oral epithelial
cells. Oral mucosal tissue usually contains connective tissue and
infiltrating lymphocytes. As shown in Figure 2A (lower panel),
lymphocytes infiltrating into normal oral mucosa showed RUNX3
expression. Therefore, we used primary cultured epithelial cells
obtained from normal oral epithelium in this study for avoiding
contamination of lymphocytes. In similar to immunohistochemical
studies (Figure 2A), 4 primary cultured epithelial cells obtained from
normal oral epithelium (#1–#4) did not express RUNX3 mRNA
(Figure 3F), indicating that expression level of RUNX3 is low or
absent in adult normal oral epithelium. We examined the RUNX3
expression after 5-aza-29-deoxycytidine treatment. RUNX3 expres-
sion was up-regulated by 5-aza-29-deoxycytidine treatment in 2
primary cultured epithelial cells (#1 and#3) (Figure 3G). Then, we
examined whether RUNX3 was silenced by methylation in adult
oral epithelial cells. We performed methylation-specific PCR in 4
primary cultured epithelial cells at the region spanning the
transcription start site of RUNX3 (No. 5–8), which is critical for
loss of the RUNX3 expression in HNSCC cells (Figure 3C).
Interestingly, 2 primary cultured epithelial cells (#1 and #2)
showed partially methylation at No. 6 and No. 7 region, and
another 2 primary cultured epithelial cells (#3 and#4) showed fully
methylation at No. 7 and No. 8 region (Figure 3H and 3I).
RUNX3 overexpression enhanced cell proliferation and
inhibited apoptosis
To know the role of RUNX3 in HNSCC, we stably transfected
an expression vector of FLAG-RUNX3 into HSC3 cells with
Table 1. Runx3 expression in normal oral mucosa and HNSCC.
Total Runx3 expression Negative* Runx3 expression Positive* P value
Normal 9 9 (100%) 0 (0%) 0.005
HNSCC 52 26 (50%) 26 (50%)
HNSCC Histology Well 31 18 (58%) 13 (42%) 0.031
Moderate 13 8 (62%) 5 (38%)
Poorly 8 0 (0%) 8 (100%)
Invasion** I & II 26 18 (69%) 8 (31%) 0.006
III & IV 26 8 (31%) 18 (69%)
Metastasis Negative 38 24 (63%) 14 (37%) 0.005
Positive 14 2 (14%) 12 (86%)
*Runx3 expression is graded as negative (less than 5% of positive cells) and positive (over 5% of positive cells).
**The grading of invasion is according to the classification described by Jakobsson et al. as patterns I, II, III and IV [38].
doi:10.1371/journal.pone.0005892.t001
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Figure 3. Methylation status in normal oral epithelial cells and HNSCC. A: RUNX3 expression was examined after 5-aza-29-deoxycytidine (5-
Aza) treatment. HSC4 cells were treated with medium containing 300 nM 5-aza-29-deoxycytidine for 72 h. After treatment, cells were collected and
examined the expression of RUNX3 mRNA by RT-PCR. B: RUNX3 CpG island and analyzed regions (No. 1–10) are shown as vertical bars.
Transcriptional start site (TSS) is located within region No. 7. C: Methylation status of RUNX3 in HNSCC cell lines. Genomic DNA was extracted from
RUNX3 Has an Oncogenic Role
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lower expression of RUNX3. We obtained stably RUNX3
overexpressing cells (Figure 4A). Interestingly, RUNX3 overex-
pression enhanced cell growth (Figure 4B). At 6day, number of
RUNX3 overexpressing cells was remarkably higher than that of
control cells. Although we examined migration and invasion,
RUNX3 overexpression did not promote migration and invasion
(Figure S2). Moreover, increased population corresponding to sub-
G1 after serum starvation was observed only in control cells, but
not in RUNX3 overexpressing cells (Figure 4C). To demonstrate
whether this increment of sub-G1 detected in control cells after
serum starvation is due to apoptosis, the level of apoptosis was
assessed by using annexin V-FITC/propidium iodide assays
(Figure 4D). Annexin V/propidium iodide double-positive cells
were observed in 1.8% of RUNX3 overexpressing cells, while in
21.7% of control cells, indicating that RUNX3 overexpression
inhibited serum starvation induced apoptosis. To confirm these
phenotypes, we examined the knockdown of RUNX3 in Ca9-22
cells, which showed RUNX3 overexpression and were resistant to
serum starvation-induced apoptosis. For knockdown of RUNX3,
we used three different siRNAs (si-RUNX3-1, si-RUNX3-2 and si-
RUNX3-3) and their cocktail. RUNX3 expression was remark-
ably silenced by si-RUNX3-1 (Figure S3A). Therefore, we used si-
RUNX3-1 for the following studies. RUNX3 siRNA transfection
reduced the expression of RUNX3 mRNA and protein in Ca9-22
cells (Figure 5A). We examined if siRNA induced a non-specific
interferon stress response. RUNX3 siRNA treatment did not
induce classic interferon-responsive genes, OAS1 and ISG54
mRNAs, indicating that RUNX3 siRNA treatment did not induce
significant interferon response (Figure S3B). As we expected,
RUNX3 siRNA inhibited the cell growth (Figure 5B). At 6day,
number of RUNX3 siRNA treated cells was remarkably lower
than that of control cells. Moreover, RUNX3 siRNA increased the
population corresponding to sub-G1 after serum starvation
(Figure 5C). Annexin V/propidium iodide double-positive cells
were observed in 10.5% of control cells, while in 18.1% of
RUNX3 knockdown cells (Figure 5D).
In addition, we examined the inhibition of apoptosis after
treatment with chemotherapeutic drug in control and RUNX3
overexpressing HNSCC (Figure 6). Control and RUNX3
overexpressing HSC3 cells were exposed for 72 hours to
adriamycin (DOX; 0.5 and 1 mg/ml), which is a chemotherapeutic
agent commonly used in the treatment of HNSCC. The sub-G1
population of RUNX3 overexpressing HSC3 cells was 7.49%,
while that of control cells was 44.76% after treatment with 1 mg/
ml of DOX (Figure 6A). Moreover, after treatment with 1 mg/ml
of DOX, Annexin V/propidium iodide double-positive cells were
observed in 25.2% of control cells, while in 8.9% of RUNX3
overexpressing cells (Figure 6B). On the other hand, Annexin V/
propidium iodide double-positive cells increased by RUNX3
knockdown (Figure 6C). Overall these suggest that RUNX3
overexpression may be involved in HNSCC development through
promoting cell growth and inhibition of apoptosis.
To know the role of RUNX3 in tumorigenesis, we examined the
tumorsphere formation by using ultra low attachment plates.
RUNX3 overexpression promoted tumorsphere formation (Figure
S4A and S4B). The average number of colonies was 535.6 and
663.3 in control and RUNX3 overexpressing cells, respectively
(Figure S4B). Moreover, RUNX3 knockdown inhibited tumor-
sphere formation (Figure S4C and S4D). The average number of
colonies was 566.0 and 161.3 in control and RUNX3 knockdown
cells, respectively (Figure S4D).
Moreover, we compared the gene transcriptional profiles
between control and RUNX3 overexpressing HSC3 cells. By
microarray analysis, 1251 genes were selectively up-regulated
(over 2-fold) and 472 genes were down-regulated (less than 0.5) in
RUNX3 overexpressing HSC3 cells (Dataset S1). Table S2 shows
the list of up-regulated genes (over 15-fold) and down-regulated
genes (less than 0.1) in RUNX3 overexpressing HSC3 cells,
respectively. Then, we used the computer program Onto-Express
to analyze the identified oxidized mRNA species and grouped
them according to cellular component or molecular function [22].
As shown in Figure S5A, 1251 genes that were up-regulated by
RUNX3 overexpression in HNSCC cells were classified into gene
ontology categories according to involvement in different biolog-
ical processes. Interestingly, up-regulated genes by RUNX3
overexpression belong to apoptosis, cell cycle and signal
transduction (Figure S5A and S5B). Moreover, some genes were
classified as being involved in keratinocyte differentiation,
keratinocyte proliferation and response to serum starvation (Figure
S5A and S5B). Thus, these focused genes potentially are important
for apoptosis, cell growth and cellular differentiation by RUNX3
overexpression. RUNX3 is known as a nuclear effecter of the
TGF-ß/BMP pathways, and a key tumor suppressor gene in the
gastric epithelium [2,3]. In vertebrate facial development, BMPs,
TGF-ß, Shh and FGFs are known to be involved [23]. In addition,
Runx3 is expressed in the tongue and palate epithelium of mouse
embryos [20]. Therefore, we suggest that RUNX3 may be
involved in the development of oral mucosa through growth factor
signaling pathways. HNSCC cell line, HOC621 cells with lower
expression of RUNX3 mRNA were treated with growth factors
including TGF-ß1, IGF, EGF, bFGF and PDGF-AA (Figure S6A).
Among these growth factors, EGF significantly enhanced RUNX3
expression in HOC621 cells. EGF enhanced RUNX3 expression
in concentration and time dependent manner (Figure S6B).
However, RUNX3 expression was not induced by growth factor
stimulation in other HNSCC cells without RUNX3 expression
due to methylation (data not shown). Moreover, we examined the
expression of EGF and EGFR and compared with RUNX3
expression. Interestingly, EGF expression was well correlated with
RUNX3 expression (Figure S6C).
Discussion
RUNX3 is inactivated in more than 80% of human gastric
cancer by CpG island hypermethylation, protein mislocalization
and point mutations [3–5]. Moreover, it has been reported that
reduced expression of RUNX3 was observed in various cancers
including bladder, liver, colon and lung cancers [5–8]. In fact,
HNSCC cell lines and was treated with bisulfite. Methylation status of promoter region (No. 1–10) was examined by methylation specific PCR method.
D: The summary of methylation and expression status of RUNX3 in HNSCC cell lines. E: Expression of Runx3 in mouse tongue epithelium of embryo
(upper panel) and adult (lower panel) mouse by immunohistochemistry. Tongue tissues of mouse embryos at embryonic day 15.5 and 10 weeks old
BALB/c mice were used. F: RUNX3 mRNA expression was examined by RT-PCR in 4 primary cultured normal oral epithelial cells (#1–#4). HSC4 cell
was used as a negative control and Ca9-22 cell was used as a positive control for RUNX3 expression. GAPDH was used as a control. G: RUNX3
expression was examined after 5-aza-29-deoxycytidine (5-Aza) treatment. Primary cultured normal oral epithelial cells (#1 and #2) were treated with
medium containing 300 nM 5-aza-29-deoxycytidine for 72 h. After treatment, cells were collected and examined the expression of RUNX3 mRNA by
RT-PCR. H: Genomic DNA was extracted from 4 primary cultured normal oral epithelial cells (#1–#4). Methylation status at region No. 5–8 was
examined by methylation specific PCR method. I: The summary of methylation and expression status of RUNX3 in normal epithelial cells.
doi:10.1371/journal.pone.0005892.g003
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gastric mucosa of Runx3-null mice develops hyperplasia due to the
stimulated proliferation and suppressed apoptosis of epithelial cells
[3]. Taken together, RUNX3 acts as a tumor suppressor in various
cancers. In this study, we confirmed the low expression of RUNX3
in various cancer cell lines by RT-PCR (Figure 1C). Expression
level of RUNX3 was well correlated with methylation status, as
previously reported [17–20]. By immunohistochemistry, RUNX3
expression was observed in normal colon mucosa, while cancer
cells did not express RUNX3 (Figure S1). Contrary to these
tumors, here we found oncogenic roles for RUNX3 in HNSCC. It
recently has been shown that RUNX3 overexpression was
observed in basal cell carcinoma of skin [13]. This distinct role
in HNSCC and skin basal cell carcinoma may be accounted for by
the pathogenesis of both types of cancer, which arise from
squamous epithelium. In fact, RUNX3 frequency of RUNX3
positive cells is low in adult skin and oral mucosa, while most
Figure 4. RUNX3 overexpression promoted cell growth and inhibited serum starvation induced apoptosis. A: Generation of RUNX3
overexpressing cells. The RUNX3/pcDNA3 plasmid or the vector alone was introduced into HSC3 cells, and the stable pool clones were obtained by
G418 selection for 2 weeks. Exogenous expression of RUNX3 mRNA and protein was examined by RT-PCR and Western blot analysis (WB). Cul1 was
used as a loading control. B: The graph shows cell growth of RUNX3 overexpressing and control HSC3 cells. Cells were plated on 24 well plates, and
trypsinized cells were counted by Cell Counter (Coulter Z1) at 0, 2, 4 and 6 day. C: RUNX3 overexpression inhibited the serum starvation induced
apoptosis. Cells were incubated for 0, 48 and 96 hours after serum starvation and fixed in 70% ethanol. Cell cycle distribution was determined by
DNA content analysis after propidium iodide staining using a flow cytometer. For each sample, 20,000 events were stored. We performed two
independent experiments. D: Flow cytometric analysis of Annexin V and propidium iodide staining in control and RUNX3 overexpressing cells after
serum starvation for 96 h. We performed two independent experiments.
doi:10.1371/journal.pone.0005892.g004
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cancer cells expressed (Figure 2) [13]. Overexpression of RUNX3
has previously been associated with functional mutations or
protein mislocalization in breast, gastric and bladder tumors [4,5].
However, functional mutations or protein mislocalization were not
found in HNSCC, indicating that RUNX3 is fully functional in
HNSCC cells. All members of the RUNX family, most notably
Runx2, are known to promote tumorigenecity in mouse models
[24,25]. In fact, RUNX3 overexpression promoted cell prolifer-
ation. In Figure 4B and 5B, RUNX3 overexpression or
knockdown affected to the cell growth from 4 day after plating.
Therefore, RUNX3 may be involved in allowance for high cell
density in addition to stimulation of cell growth. Moreover,
RUNX3 overexpression inhibited serum starvation induced
apoptosis and chemotherapeutic drug induced apoptosis in vitro
in HNSCC cells (Figures 4–6). Interestingly, RUNX3 overexpres-
sion promoted tumorigenesis, demonstrated by tumorsphere
formation assay (Figure S4). These findings may be implicated
in RUNX3 related malignant behaviors of HNSCC including
Figure 5. RUNX3 knockdown inhibited cell growth and enhanced serum starvation induced apoptosis. A: RUNX3 silencing by small
interfering RNA. Logarithmically growing Ca9-22 cells with RUNX3 expression were seeded at a density of 105cells/6 cm dish and transfected with
oligos twice (at 24 and 48 hr after replating). Forty-eight hours after the last transfection, cells were collected and RUNX3 mRNA and protein
expression was examined by RT-PCR and Western blot analysis. B: The graph shows that cell growth of RUNX3 siRNA treated and control Ca9-22 cells.
Cells were plated on 24 well plates, and trypsinized cells were counted by Cell Counter at 0, 2, 4 and 6 day. C: RUNX3 siRNA enhanced the serum
starvation induced apoptosis. Cell cycle distribution was determined by DNA content analysis after propidium iodide staining using a flow cytometer.
For each sample, 20,000 events were stored. We performed two independent experiments. D: Flow cytometric analysis of Annexin V and propidium
iodide staining in control and RUNX3 knockdown cells after serum starvation for 96 h. We performed two independent experiments.
doi:10.1371/journal.pone.0005892.g005
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invasiveness and metastasis (Table 1). Comparing the gene
expression profile between control and RUNX3 overexpressing
HNSCC cells revealed that several genes were selectively up-
regulated and down-regulated (Table S2). CXCL14, IGFBP2 and
EphA4 receptor were up-regulated, and fibronectin 1 was down-
regulated in RUNX3 overexpressing HNSCC cells. Although
CXCL14 suppresses tumor growth in some type of cancer,
CXCL14 is involved in invasion of pancreatic cancer [26].
Moreover, IGFBP-2 is a highly sensitive marker of malignant
progression in different tumors and potentially involved in anti-
apoptosis, angiogenesis, and metastasis during cancer progression
[27]. EphA4 receptor also promotes cancer cell growth [28]. In
addition, classification into gene ontology categories according to
involvement in different biological processes showed that several
genes involved in apoptosis and cell cycle were up-regulated by
RUNX3 overexpression (Figure S5). It is interesting to examine
the correlation between RUNX3 and these molecules. The
findings identified by microarray analysis may help future
experiments for clarifying the detailed role of RUNX3 in the
development of HNSCC.
DNA methylation plays an important role in the establishment
and maintenance of the program of gene expression. The pattern
of 5-methylcytosine distribution in the genome is unique for each
cell type and is established in embryogenesis as a result of balance
between DNA methylation and demethylation [29,30]. It recently
has been revealed that Runx3 is expressed in the tongue and
palate epithelium of mouse embryos and Runx3 expression
disappears in newborn mice [20]. Here, we also confirmed that
Runx3 expression was observed in tongue epithelium of embryo,
but not in adult tongue epithelium (Figure 3E). Interestingly, we
demonstrated that RUNX3 methylation of its promoter region was
observed in normal epithelial cells (Figure 3H and 3I), suggesting
that RUNX3 may be silenced by methylation in adult normal oral
epithelium. However, there may be another possibility, such as
transcriptional modulation by traditional activators or repressors,
in addition to the regulation of RUNX3 expression by
methylation. Moreover, methylation of its promoter region was
observed in HNSCC cells without RUNX3 expression (Figure 3C
and 3D). Therefore, these findings indicate that RUNX3
expression in HNSCC may be caused by demethylation during
cancer development (Figure 7). In malignant tumor, the level of
general demethylation and the frequency of demethylation
increase with tumor progression [31,32], and demethylation of
individual CpG dinucleotides located in C-MYC, Ha RAS, and
ERB-A1 proto-oncogene was revealed in human tumors [33–36].
Detailed mechanism of RUNX3 regulation in normal adult oral
epithelium and HNSCC requires further experiments.
RUNX3 is expressed in the gastrointestinal tract of mouse and
human [3], and RNT, a homolog of the RUNX family in C.
elegans, is involved in the development of a functional epidermis
and gut [37]. RUNX3 is known as a nuclear effector of the
functional BMP/TGF-ß pathways, and a key tumor suppressor
gene in the gastric epithelium [2,3]. In vertebrate facial
development, BMPs, TGF-ß, Shh and FGFs are known to be
involved [23]. As RUNX3 expression in tongue and palatal
epithelium is observed only in embryonic stage, RUNX3 may be
involved in the development of oral mucosa through some
signaling pathways such as TGF-ß/BMP, Shh and FGF. We
treated growth factors such as TGF-ß1, IGF, EGF, bFGF, and
PDGF-AA in HNSCC cells with RUNX3 expression and found
that EGF enhanced RUNX3 expression. In HNSCC, RUNX3
overexpression may be caused by some stimulation including EGF
(Figure 7). To know the mechanism of RUNX3 overexpression in
HNSCC requires further studies.
Overall we suggest that i) RUNX3 has an oncogenic role in
HNSCC, ii) RUNX3 expression observed in HNSCC may be
caused in part by demethylation during cancer development, and
iii) RUNX3 expression can be a useful marker for predicting
malignant behavior and the effect of chemotherapeutic drugs in
HNSCC.
Figure 7. Schematic model of RUNX3 overexpression in HNSCC. In oral epithelium of embryo, RUNX3 is expressed and may be induced by
some signaling pathways such as BMP/TGF-ß, Shh and FGF. After birth, RUNX3 may be methylated of its promoter and/or transcriptional repression in
oral epithelial cells. RUNX3 may be caused by demethylation or transcriptional modulation during cancer development. In aggressive HNSCC,
unknown stimulation may enhance RUNX3 expression.
doi:10.1371/journal.pone.0005892.g007
Figure 6. RUNX3 overexpression inhibited chemotherpeutic drug induced apoptosis. A: Adriamycin (Dox, 0, 0.5 and 1 mg/ml) was treated
for 72 hours in control and RUNX3 overexpressing HSC3 cells. Cell cycle distribution was determined by DNA content analysis after propidium iodide
staining using a flow cytometer. For each sample, 20,000 events were stored. Percentage of sub-G1 population is indicated. We performed two
independent experiments with triplicate wells per condition. Representative data is shown. B: Flow cytometric analysis of Annexin V and propidium
iodide staining in control and RUNX3 overexpressing cells after DOX treatment for 72 h at the indicated doses. C: Flow cytometric analysis of Annexin
V and propidium iodide staining in control and RUNX3 knockdown cells after DOX treatment for 72 h at the indicated doses. We performed two
independent experiments.
doi:10.1371/journal.pone.0005892.g006
RUNX3 Has an Oncogenic Role
PLoS ONE | www.plosone.org 11 June 2009 | Volume 4 | Issue 6 | e5892
Supporting Information
Table S1
Found at: doi:10.1371/journal.pone.0005892.s001 (0.05 MB PPT)
Table S2
Found at: doi:10.1371/journal.pone.0005892.s002 (0.12 MB
DOC)
Figure S1
Found at: doi:10.1371/journal.pone.0005892.s003 (0.35 MB TIF)
Figure S2
Found at: doi:10.1371/journal.pone.0005892.s004 (0.39 MB TIF)
Figure S3
Found at: doi:10.1371/journal.pone.0005892.s005 (0.17 MB TIF)
Figure S4
Found at: doi:10.1371/journal.pone.0005892.s006 (0.31 MB TIF)
Figure S5
Found at: doi:10.1371/journal.pone.0005892.s007 (0.90 MB TIF)
Figure S6
Found at: doi:10.1371/journal.pone.0005892.s008 (0.20 MB TIF)
Dataset S1
Found at: doi:10.1371/journal.pone.0005892.s009 (0.88 MB
XLS)
Acknowledgments
We thank Dr. Gaffney (University of Minnesota Medical School) for
providing us the Gene Chips data of 41 primary HNSCC and 13 normal
tissues, Dr. Kamata (Hiroshima University) for providing us the HNSCC
cell lines, Dr. Shimamoto (Prefectural University of Hiroshima) for
providing us the specimens of colon cancer, Dr. Tahara (Hiroshima
University) for providing us the cancer cell lines, Ms. Imaoka (Nihon
University School of Dentistry at Matsudo) for supporting microarray
analysis and Dr. Siriwardena (Hiroshima University) for technical
assistance. We also thank Dr. Ito Y and Dr. Ito K (Institute of Molecular
and Cell Biology, Singapore) for providing reagents and helpful discussion.
Author Contributions
Conceived and designed the experiments: YK. Performed the experiments:
TT YK SI IO YA. Analyzed the data: TT YK SI IO YA TT. Contributed
reagents/materials/analysis tools: YK TF HK YA. Wrote the paper: YK
TT.
References
1. Ito Y (2004) Oncogenic potential of the RUNX gene family: ‘Overview’.
Oncogene 23: 4198–4208.
2. Bae SC, Takahashi E, Zhang YW, Ogawa E, Shigesada K, et al. (1995) Cloning,
mapping and expression of PEBP2aC, a third gene encoding the mammalian
runt domain. Gene 159: 245–248.
3. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, et al. (2002) Causal relationship
between the loss of RUNX3 expression and gastric cancer. Cell 109: 113–124.
4. Ito K, Liu Q, Salto-Tellez M, Yano T, Tada K, et al. (2005) RUNX3, a novel
tumor suppressor, is frequently inactivated in gastric cancer by protein
mislocalization. Cancer Res 65: 7743–7750.
5. Kim WJ, Kim EJ, Jeong P, Quan C, Kim J, et al. (2005) RUNX3 inactivation by
point mutations and aberrant DNA methylation in bladder tumors. Cancer Res
65: 9347–9354.
6. Ku JL, Kang SB, Shin YK, Kang HC, Hong SH, et al. (2004) Promoter
hypermethylation downregulates RUNX3 gene expression in colorectal cancer
cell lines. Oncogene 23: 6736–6742.
7. Mori T, Nomoto S, Koshikawa K, Fujii T, Sakai M, et al. (2005) Decreased
expression and frequent allelic inactivation of the RUNX3 gene at 1p36 in
human hepatocellular carcinoma. Liver Int 25: 380–388.
8. Yanada M, Yaoi T, Shimada J, Sakakura C, Nishimura M, et al. (2005)
Frequent hemizygous deletion at 1p36 and hypermethylation downregulate
RUNX3 expression in human lung cancer cell lines. Oncol Rep 14: 817–822.
9. Kim TY, Lee HJ, Hwang KS, Lee M, Kim JW, et al. (2004) Methylation of
RUNX3 in various types of human cancers and premalignant stages of gastric
carcinoma. Lab Invest 84: 479–484.
10. Mao L, Hong WK, Papadimitrakopoulou VA (2004) Focus on head and neck
cancer. Cancer Cell 5: 311–316.
11. Fidler IJ (1990) Critical factors in the biology of human cancer metastasis: Twenty-
eighth GHA Clowes Memorial Award Lecture. Cancer Res 50: 6130–6138.
12. Ginos MA, Page GP, Michalowicz BS, Patel KJ, Volker SE, et al. (2004)
Identification of a Gene Expression Signature Associated with Recurrent Disease
in Squamous Cell Carcinoma of the Head and Neck. Cancer Res 64: 55–63.
13. Salto-Tellez M, Peh BK, Ito K, Tan SH, Chong PY, et al. (2006) RUNX3 protein
is overexpressed in human basal cell carcinomas. Oncogene 25: 7646–7649.
14. Kitajima S, Kudo Y, Ogawa I, Bashir T, Kitagawa M, et al. (2004) Role of Cks1
overexpression in oral squamous cell carcinomas: cooperation with Skp2 in
promoting p27 degradation. Am J Pathol 165: 2147–2155.
15. Homma N, Tamura G, Honda T, Matsumoto Y, Nishizuka S, et al. (2006)
Spreading of methylation within Runx3 CpG island in gastric cancer. Cancer
Sci 97: 51–56.
16. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001)
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured
mammalian cells. Nature 411: 494–498.
17. Cheng CK, Li L, Cheng SH, Lau KM, Chan NPH, et al. (2008) Transcriptional
repression of the RUNX3/AML2 gene by the t(8;21) and inv(16) fusion proteins
in acute myeloid leukemia. Blood 112: 3391–3402.
18. Takahashi T, Shigematsu H, Shivapurkar N, Reddy J, Zheng Y, et al. (2006)
Aberrant promoter methylation of multiple genes during multistep pathogenesis
of colorectal cancers. Int J Cancer 118: 924–931.
19. Oshimo Y, Oue N, Mitani Y, Nakayama H, Kitadai Y, et al. (2004) Frequent
Loss of RUNX3 Expression by Promoter Hypermethylation in Gastric
Carcinoma. Pathobiology 71: 137–143.
20. Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito K, et al. (2006) RUNX3 Is
Frequently Inactivated by Dual Mechanisms of Protein Mislocalization and
Promoter Hypermethylation in Breast Cancer. Cancer Res 66: 6512–6520.
21. Yamamoto H, Ito K, Kawai M, Murakami Y, Bessho K, Ito Y (2006) Runx3
expression during mouse tongue and palate development. Anat Rec A Discov
Mol Cell Evol Biol 288: 695–699.
22. Draghici S, Khatri P, Bhavsar P, Shah A, Krawetz SA, et al. (2003) Onto-Tools,
the toolkit of the modern biologist: Onto-Express, Onto-Compare, Onto-Design
and Onto-Translate. Nucleic Acids Res 31: 3775–3781.
23. Francis-West P, Ladher R, Barlow A, Graveson A (1998) Signaling interactions
during facial development. Mech Dev 75: 3–28.
24. Cameronm ER, Neil JC (2004) The Runx genes: lineage-specific oncogenes and
tumor suppressors. Oncogene 23: 4308–4314.
25. Yanagida M, Osato M, Yamashita N, Liqun H, Jacob B, et al. (2005) Increased
dosage of Runx1/AML1 acts as a positive modulator of myeloid leukemogenesis
in BXH2 mice. Oncogene 24: 4477–4485.
26. Wente MN, Mayer C, Gaida MM, Michalski CW, Giese T, et al. (2008)
CXCL14 expression and potential function in pancreatic cancer. Cancer Lett
259: 209–217.
27. Hoeflich A, Reisinger R, Lahm H, Kiess W, Blum WF, et al. (2001) Insulin-like
growth factor-binding protein 2 in tumorigenesis: protector or promoter?
Cancer Res 61: 8601–8610.
28. Iiizumi M, Hosokawa M, Takehara A, Chung S, Nakamura T, et al. (2006)
EphA4 receptor, overexpressed in pancreatic ductal adenocarcinoma, promotes
cancer cell growth. Cancer Sci 97: 1211–1216.
29. Razin A, Riggs AD (1984) DNA methylation and gene function. Science 210:
604–610.
30. Razin A, Shemer R (1995) DNA methylation in early development. Human Mol
Genet 4: 1751–1755.
31. Gama-Sosa MA, Slagel VA, Trewyn RW, Oxenhandler R, Kuo KC, et al.
(1983) The 5-methylcytosine content of DNA from human tumors. Nucleic
Acids Res 11: 6883–6894.
32. Kim YI, Giuliano A, Hatch KD, Schneider A, Nour MA, et al. (1994) Global
DNA hypomethylation increases progressively in cervical dysplasia and
carcinoma. Cancer 74: 893–899.
33. Borrello MG, Pierotti MA, Tamborini E, Biassoni D, Rizzetti MG, et al. (1992)
DNA methylation of coding and non-coding regions of the human H-RAS gene
in normal and tumor tissues. Oncogene 7: 269–275.
34. Cheah MS, Wallace CD, Hoffman RM (1984) Hypomethylation of DNA in
human cancer cells: a site-specific change in the c-myc oncogene. J Natl Cancer
Inst 73: 1057–1065.
35. Fienberg AP, Vogelstein B (1983) Hypomethylation of ras oncogenes in primary
human cancers. Biochem Biophys Res Commun 111: 47–54.
36. Lipsanen V, Leinonen P, Alhonen L, Janne J (1988) Hypomethylation of
ornithine decarboxylase gene and erb-A1 oncogene in human chronic lymphatic
leukemia. Blood 72: 2042–2044.
37. Nam S, Jin YH, Li QL, Lee KY, Jeong GB, Ito Y, et al. (2001) Expression
pattern, regulation, and biological role of Runt domain transcription factor, run,
in Caenorhabditis elegans. Mol Cell Biol 22: 547–554.
38. Jacobsson PA, Eneroth GM, Killander D, Moberger G, Martensson B (1973)
Histologic classification and grading of malignancy in carcinoma of the larynx.
Acta Radiol 12: 1–7.
RUNX3 Has an Oncogenic Role
PLoS ONE | www.plosone.org 12 June 2009 | Volume 4 | Issue 6 | e5892
